# A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

> **NCT00358956** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 19 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** ZD6474 (vandetanib)

## Key facts

- **NCT ID:** NCT00358956
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-01
- **Final completion:** 2014-05
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358956, "A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00358956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*